Striational autoantibodies: Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow

N. Cikes, M. Y. Momoi, C. L. Williams, F. M. Howard, H. C. Hoagland, S. Whittingham, Vanda A Lennon

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Striational autoantibodies (StrAb) are a useful serologic marker of thymoma in patients with myasthenia gravis (MG). We compared a standard immunofluorescence method with a new enzyme immunoassay (EIA) for detection of StrAb. Retrospective testing of 264 stored sera by the two methods yielded well-correlated results (58 sera were positive by both assays; r = 0.8). For 104 patients with spontaneously acquired MG or thymoma, results were 100% concordant, of which 53% were positive. For 34 recipients of D-penicillamine, StrAb were found in 15% by EIA and in 6% by immunofluorescence. StrAb were detected in two of four bone marrow recipients by EIA and in one by immunofluorescence. Prospective testing of 434 fresh sera (of which 49 were positive by the two methods) yielded discordant results in only 4. Serial EIA quantitation of StrAb in two patients with MG and thymoma proved useful in monitoring immunosuppressant therapy and in a third patient predicted recurrence of the tumor. A high prevalence of StrAb was detected by both assays in elderly patients with spontaneous MG, but StrAb were more readily quantifiable by EIA. The EIA method proved to be highly sensitive and specific for detecting StrAb in patients with thymoma with and without MG, in patients treated with D-penicillamine, and in those with graft-versus-host disease after bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)474-481
Number of pages8
JournalMayo Clinic Proceedings
Volume63
Issue number5
StatePublished - 1988
Externally publishedYes

Fingerprint

Penicillamine
Thymoma
Myasthenia Gravis
Immunoenzyme Techniques
Autoantibodies
Bone Marrow
Fluorescent Antibody Technique
Serum
Graft vs Host Disease
Immunosuppressive Agents
Bone Marrow Transplantation
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Striational autoantibodies : Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. / Cikes, N.; Momoi, M. Y.; Williams, C. L.; Howard, F. M.; Hoagland, H. C.; Whittingham, S.; Lennon, Vanda A.

In: Mayo Clinic Proceedings, Vol. 63, No. 5, 1988, p. 474-481.

Research output: Contribution to journalArticle

Cikes, N. ; Momoi, M. Y. ; Williams, C. L. ; Howard, F. M. ; Hoagland, H. C. ; Whittingham, S. ; Lennon, Vanda A. / Striational autoantibodies : Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. In: Mayo Clinic Proceedings. 1988 ; Vol. 63, No. 5. pp. 474-481.
@article{a96b1ea4599548619e2230bb9b4e16ed,
title = "Striational autoantibodies: Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow",
abstract = "Striational autoantibodies (StrAb) are a useful serologic marker of thymoma in patients with myasthenia gravis (MG). We compared a standard immunofluorescence method with a new enzyme immunoassay (EIA) for detection of StrAb. Retrospective testing of 264 stored sera by the two methods yielded well-correlated results (58 sera were positive by both assays; r = 0.8). For 104 patients with spontaneously acquired MG or thymoma, results were 100{\%} concordant, of which 53{\%} were positive. For 34 recipients of D-penicillamine, StrAb were found in 15{\%} by EIA and in 6{\%} by immunofluorescence. StrAb were detected in two of four bone marrow recipients by EIA and in one by immunofluorescence. Prospective testing of 434 fresh sera (of which 49 were positive by the two methods) yielded discordant results in only 4. Serial EIA quantitation of StrAb in two patients with MG and thymoma proved useful in monitoring immunosuppressant therapy and in a third patient predicted recurrence of the tumor. A high prevalence of StrAb was detected by both assays in elderly patients with spontaneous MG, but StrAb were more readily quantifiable by EIA. The EIA method proved to be highly sensitive and specific for detecting StrAb in patients with thymoma with and without MG, in patients treated with D-penicillamine, and in those with graft-versus-host disease after bone marrow transplantation.",
author = "N. Cikes and Momoi, {M. Y.} and Williams, {C. L.} and Howard, {F. M.} and Hoagland, {H. C.} and S. Whittingham and Lennon, {Vanda A}",
year = "1988",
language = "English (US)",
volume = "63",
pages = "474--481",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Striational autoantibodies

T2 - Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow

AU - Cikes, N.

AU - Momoi, M. Y.

AU - Williams, C. L.

AU - Howard, F. M.

AU - Hoagland, H. C.

AU - Whittingham, S.

AU - Lennon, Vanda A

PY - 1988

Y1 - 1988

N2 - Striational autoantibodies (StrAb) are a useful serologic marker of thymoma in patients with myasthenia gravis (MG). We compared a standard immunofluorescence method with a new enzyme immunoassay (EIA) for detection of StrAb. Retrospective testing of 264 stored sera by the two methods yielded well-correlated results (58 sera were positive by both assays; r = 0.8). For 104 patients with spontaneously acquired MG or thymoma, results were 100% concordant, of which 53% were positive. For 34 recipients of D-penicillamine, StrAb were found in 15% by EIA and in 6% by immunofluorescence. StrAb were detected in two of four bone marrow recipients by EIA and in one by immunofluorescence. Prospective testing of 434 fresh sera (of which 49 were positive by the two methods) yielded discordant results in only 4. Serial EIA quantitation of StrAb in two patients with MG and thymoma proved useful in monitoring immunosuppressant therapy and in a third patient predicted recurrence of the tumor. A high prevalence of StrAb was detected by both assays in elderly patients with spontaneous MG, but StrAb were more readily quantifiable by EIA. The EIA method proved to be highly sensitive and specific for detecting StrAb in patients with thymoma with and without MG, in patients treated with D-penicillamine, and in those with graft-versus-host disease after bone marrow transplantation.

AB - Striational autoantibodies (StrAb) are a useful serologic marker of thymoma in patients with myasthenia gravis (MG). We compared a standard immunofluorescence method with a new enzyme immunoassay (EIA) for detection of StrAb. Retrospective testing of 264 stored sera by the two methods yielded well-correlated results (58 sera were positive by both assays; r = 0.8). For 104 patients with spontaneously acquired MG or thymoma, results were 100% concordant, of which 53% were positive. For 34 recipients of D-penicillamine, StrAb were found in 15% by EIA and in 6% by immunofluorescence. StrAb were detected in two of four bone marrow recipients by EIA and in one by immunofluorescence. Prospective testing of 434 fresh sera (of which 49 were positive by the two methods) yielded discordant results in only 4. Serial EIA quantitation of StrAb in two patients with MG and thymoma proved useful in monitoring immunosuppressant therapy and in a third patient predicted recurrence of the tumor. A high prevalence of StrAb was detected by both assays in elderly patients with spontaneous MG, but StrAb were more readily quantifiable by EIA. The EIA method proved to be highly sensitive and specific for detecting StrAb in patients with thymoma with and without MG, in patients treated with D-penicillamine, and in those with graft-versus-host disease after bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0023923563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023923563&partnerID=8YFLogxK

M3 - Article

C2 - 3283472

AN - SCOPUS:0023923563

VL - 63

SP - 474

EP - 481

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -